Benign Positional Vertigo in Emergency Medicine Medication
- Author: Andrew K Chang, MD; Chief Editor: Rick Kulkarni, MD more...
Medication Summary
Medical treatment for benign positional vertigo (BPV) is generally ineffective but may be used to lessen the symptoms.[4] The natural history of BPV is to resolve with time as the otoliths eventually dissolve while in the semicircular canals.
The use of vestibular suppressants is based on the sensory conflict theory, in which sensory input is compared from different systems, and if a conflict exists, then nausea and vomiting result. Over time, habituation occurs. Several main neurotransmitters mediate these functions: GABA, acetylcholine, and histamine/serotonin.
Antihistaminic antiemetics
Class Summary
The antihistaminic antiemetics block the emetic response. For patients with severe vertigo or vomiting, intravenous promethazine (Phenergan) is the drug of choice; prochlorperazine (Compazine) is not very useful in this context. Meclizine is given orally and does not work fast enough to be effective acutely. Most antiemetics have anticholinergic activity as well.
Promethazine (Phenergan, Anergan, Prorex)
Antidopaminergic agent used to treat emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in the brain and reduces stimuli to brainstem reticular system. Also has cross reactivity with the cholinergic receptors.
Meclizine (Antivert, Antrizine, Dramamine)
Decreases excitability of middle ear labyrinth and blocks conduction in middle ear vestibular-cerebellar pathways. These effects are associated with relief of nausea and vomiting.
Benzodiazepines
Class Summary
These agents block the GABA receptors and serve as the "brakes" to the system. Although they can be used acutely in the ED, they are not recommended for long-term use because they interfere with the process of vestibular rehabilitation.
Lorazepam (Ativan)
Sedative hypnotic in benzodiazepine class that has short time to onset and relatively long half-life. Depresses all levels of CNS, including limbic and reticular formation, probably through increased action of GABA, a major inhibitory neurotransmitter.
Anticholinergics
Class Summary
These agents block the conflict signal sites.
Scopolamine (Isopto, Scopace Tablet)
Blocks action of acetylcholine at parasympathetic sites in the smooth muscle, secretory glands, and CNS. Antagonizes histamine and serotonin action.
Transdermal scopolamine may be most effective agent for motion sickness. Use in the treatment of BPV is limited by slow onset of action.
Dimenhydrinate (Dimetabs, Dramamine)
Mixture of 1:1 salt consisting of 8-chlorotheophylline and diphenhydramine. Believed to be useful, particularly in treatment of vertigo. Diminishes vestibular stimulation and depresses labyrinthine function through central anticholinergic effects. However, prolonged treatment may decrease rate of recovery of vestibular injuries.
Sympathomimetic
Class Summary
These agents are useful in reversing soporific effects of vestibular sedatives.
Methylphenidate (Ritalin)
Piperidine derivative most commonly prescribed; efficacy has been demonstrated in randomized, double-blind, dose-response, and placebo-controlled trials. Stimulates cerebral cortex and subcortical structures.
Froehling DA, Silverstein MD, Mohr DN, Beatty CW, Offord KP, Ballard DJ. Benign positional vertigo: incidence and prognosis in a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. Jun 1991;66(6):596-601. [Medline].
[Guideline] Bhattacharyya N, Baugh RF, Orvidas L, Barrs D, Bronston LJ, Cass S, et al. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. Nov 2008;139(5 Suppl 4):S47-81. [Medline]. [Full Text].
Furman JM, Cass SP. Benign paroxysmal positional vertigo. N Engl J Med. Nov 18 1999;341(21):1590-6. [Medline].
[Guideline] Fife TD, Iverson DJ, Lempert T, Furman JM, Baloh RW, Tusa RJ, et al. Practice parameter: therapies for benign paroxysmal positional vertigo (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. May 27 2008;70(22):2067-74. [Medline]. [Full Text].
Epley JM. Particle repositioning for benign paroxysmal positional vertigo. Otolaryngol Clin North Am. Apr 1996;29(2):323-31. [Medline].
Kim AS, Fullerton HJ, Johnston SC. Risk of vascular events in emergency department patients discharged home with diagnosis of dizziness or vertigo. Ann Emerg Med. Jan 2011;57(1):34-41. [Medline].
Baloh RW. Dizziness and vertigo. In: Samuels MA, Feske S. Office Practice of Neurology. London: Churchill Livingstone; 1996:83-91.
Brandt T, Daroff RB. Physical therapy for benign paroxysmal positional vertigo. Arch Otolaryngol. Aug 1980;106(8):484-5. [Medline].
Chang AK, Schoeman G, Hill M. A randomized clinical trial to assess the efficacy of the Epley maneuver in the treatment of acute benign positional vertigo. Acad Emerg Med. Sep 2004;11(9):918-24. [Medline].
Froehling DA, Bowen JM, Mohr DN, et al. The canalith repositioning procedure for the treatment of benign paroxysmal positional vertigo: a randomized controlled trial. Mayo Clin Proc. Jul 2000;75(7):695-700. [Medline].
Lempert T, Gresty MA, Bronstein AM. Benign positional vertigo: recognition and treatment. BMJ. Aug 19 1995;311(7003):489-91. [Medline].
Marill KA, Walsh MJ, Nelson BK. Intravenous Lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. Ann Emerg Med. Oct 2000;36(4):310-9. [Medline].
Massoud EA, Ireland DJ. Post-treatment instructions in the nonsurgical management of benign paroxysmal positional vertigo. J Otolaryngol. Apr 1996;25(2):121-5. [Medline].
Troost BT, Patton JM. Exercise therapy for positional vertigo. Neurology. Aug 1992;42(8):1441-4. [Medline].

